Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pods, veritas in responding. Yet, on the business/ investment side, the company needs to present update(s).
Respectfully, I don't think overhyped at all. This positive clinical trial result with more to come is news worthy. I agree that MARKER T. needs to gather prepare and issue more than one Press Release covering PC results and TPIV results.
Oncologists have an increasing awareness and a few are beginning to support trial entrance. The public should also be accurately updated... of course in my opinion... would be helpful to know the opinions of others.
$4.64 open...most, if not all shareholders are underwater and still no meaningful executive defense of the share price with any news.
Yes,the focus is on the science being clinical trials by others.
No, the financial side ( needing to raise capital efficiently) and increasing shareholder wealth is not visible.
I'd like to know the vision and goals of each department head..
It seems few others have similar concerns from looking at this thread ... reduced to technical trading.
The bell rings, Oct.01, begins the 4th quarter... The company is to release updates on TPIV 110 and 200 among other corporate activities. We can only hope that the SP needle moves significantly up.
What do you think us the real value of MARKER, setting aside the current low $5,00?
A neutral thought.... M&A pro forma analysis is repeatedly done and reported within BP.
Re: MARKER pipeline...
For each C/trial.
Population: How many desease impacted domestically?
What is estimated P rate?
Revenue: What is estimated revenue per each full treatment based on P rate?
Expense: Direct cost of product?
Ancillary cost and amortization of research cost?
Profit margin per patient, cumulative per year and 5 year forward scan?
Wouldn't it be great if we had one talented person who could take a crack at this? BP has. It becomes a part of their constant " acquisition process." We do have some data on PC population and cost estimate.
Summary: We know our excellent management team. We know much of the science. We are stymied at the low valuation of share price. We believe that some algorithm trades likely are taking place. What we would benefit from is a multi Pro forma.
Of course, in my opinion, only.
Can't we walk and chew gum at the same time?
PL, a thoughtful response. Most, I can agree with.. but investment groups do care about ROI, efficient use of capital, and scan outlook.
I don't know the strategy of any or each.
I'll hope that a consult will happen on achieving a fair valuation of the company within the next few months.
As always, thanks P L for engaging.
PL, reasonable and thoughtful response as usual, my friend.
What is becoming an investment reality issue us this... looking into your Q2,'20, the share price is low range bound for over year. That is " dead money" and some to many will look at " lost opportunity" costs and " walk."
The company has sought and hired high priced talent... I would have expect a lot more in "action and goal setting." The company has to become more than science and cash flow sensitive, but also now much more... shareholder sensitive. I'd bet that some of the bigger holders of shares know to make use of capital and dislike no movement. Yes, my opinion, but I have others thinking the same... Peter, look at a larger picture, please.
Years ago, this board was filled with science by RW. Blu, PL and others. Then it became a board on confidence keeping.I recall in January (27?) PL suggested a year end share price if between $15 & $20. Recent months has a lot of disappointment and technical traders.
I'm not fussy, just get the TPIV and PC data and updates to us within the next 80 days..pretty please with whatever you want on it P. H.
Over the past 3+ months, this share price has gone no wheres.... any increase is dependent on positive news releases. Are we not expecting postive results from the various TPIV projects?
Marker has a highly qualified executive staff... every area is now covered.
Yet, Mayo operates the science independently, as does Baylor and others.
Do you ever wonder what tasks are undertaken in the office on any day?
Some days with nothing going on?
As large retail shareholder, I would appreciate a real detailed update of U&C goals.
Dow/ market up 400+ points, everything is " green" except Marker. Some few really dislike this great company..
Attila... agree.. this board has gone downhill, just like the share price. A few of us remember facts, data, and good DD and communication with Peter H. We were guided by the likes of RW, Blu, our PL, and another whose name escapes me.
Over on the YAHOO mb, they talk science, journals, and prospects.
Perhaps disclosure, transparent news releases in this Sept. and monthly to Year end will stabilize this board and significantly increase share price. On a comparative ' micro cap stock, we ought to be heading to $30.. not flat lined below $9.00
I was reading about the stage 4 pancreatic cancer recovery status and noted that in the U.S. 57,000 new cases each year and 47,000 deaths... like each of you, I hope MRKR has the cure or big part of it.
From a business side, pricing and profit creates s/p value..any EPS/ multiplier financial thoughts on this?
From a low of today ( thus far) of $4.64 against the 52 week high of $10.60.. down 65%...pathetic...
Now: $4.66.. what the??
$4.79... are you kidding me?
To management... yes, c/ trials take time. Yes, Mayo and Sloan responds as they decide. But, isn't there any postive comments you can make to defend this " off the cliff" share price?
As I submitted yesterday, I am very concerned about this possible corporate failure.
$4.94 close on low volume.. retail investor uncertainty and angst. Very understandable. Likely, most everyone is underwater, me at ave.$7.15...
The conundrum is good initial pancreatic clinic results, expectant good results from TPIV 110 and 200. Add to this,, two stellar hires to an outstanding science team... you would think, expect a much higer share price. $20-$30 dollars
But..... we sink lower every week, fearful that the company will be destroyed or bought out for penny's.
So... wishing and hoping and board outbreaks are useless... our future rests squarely in the hands, minds, and communications of and by the company and Peter. For the first time in many years, nervous? Honestly.... yes. 70,000 shares.. to many? I sincerely hope not, but have no clear way of knowing, just like each of you. But, if yhe company succeeds, PL big time dinner on me in your ball park or tennis court or how ever they name it now days
Supreme Court justice Ruth Ginzburg has compleyed 3 weeks of targeted radiation for a tumor on the pancreas at Sloan Kettering... lets see how this turns out and would it be better if she had our treatment.
Who ever is the person standing by the ' share price' elevator, on the $5.00 floor.... keep your dang finger off and quit pressing the down button.
It is both amazing and disheartening that every time great news comes out, the SP needle moves up slightly,, twitches,, then falls back to another day, week, or month of extreme undervalue.
Been in this for years, experienced reverse splits, read lots of opinions, way underwater, but holding on
To me, this is a very big addition to the 11. Adding this (Irish girl, humor intended) , Nadia Agopyan VP, with her credentials and lengthy experience in the new MTKR area of Regulatory Affairs... suggests many near and mid term possibilities of corporate action based on progressing pipelines of cancer cures.
I'm very impressed. This leads me to think of several positive news releases in third and fourth quarter 2019. PH and team exects.... keep the momentum in science going.
Unless there is a negative item that a select few know,but that we do NOT know... then this S/P off the cliff is unfathomable..
The only person here who knows Peter H. Is our trusted Phantom lord.. I along with countless others ask you to contact and see what can be done to stop this retail company owners destruction. At the minimum be aware the some disgruntled will file a law suit... peter, a part of your job is market place relations with share holders.
No one projected a price decline from $9.00, other than the mb village idiot.
It would be wise to stay away from the "wishing and hoping" , the unsubstantiated opinion being posted as " fact", and better to know..This 50% drop from $9.00 suggests someone(s) know something or are flose to knowing more than we do and it seems not to be good. Since the $9.00 level, how many shares have been traded?
In the week before the Friday leak, how many shares traded?
PH would do well to defend the SP, as qouls he expected honestly and with clarity. I'm done buying, under water ( drowning) and can only await some PR from the company. That is the only reality.
123Tom... chart reading of MRKR is about as accurate as the tea reading I had today. Mine said " We're getting pounded.," Tomorrow pre market is already in the 5's.
No relief..40% down.. painfully pathetic.
Yes, RKmatters and Blue were the ones that drew me in. Like you, PL, and a few others, would appreciate hearing from them. Been a long time here, long karge losses... if only we could rise to $10+..soon, rather than hear another year or two.
Currently down in pre market. Possible that one or more of our great posters would update meeting high lights? Some of us can't get time off to listen.
As with you, I hope for great news abd share price increase... beyond $9.00.
From $9.00, I took a hit of $154,000, so like all of here, I can only hope that pn Monday P.H and company present meaningful data and convince the listening analysts and investing world that this PC P1/2 is vital to patients with more improvements to come. Perhaps inserting the entire pipeline success and future.
If not able, we're heading lower due to shorts and MM's. IMO, Friday should never have happened. I wasn't a " cheer leader" but now more than cautious about the next 6 months... dilution and sparse PR's.
I also realize that in the company, paychecks continue, research goes on, and we are stuck with it. Good luck Peter, use all your honed skills.
$6.33,-$2.37 on 3.4 million volume, science results receive a "Bronx cheer"..
... I would love to know or have heard yhe intra office chatter and resolution today.
Wouldn't you?
More than a million shares traded in less than an hour.... 22% down.. ouch!
There is the science by BMC and a cautious ser of responses which gas not been well received.
There also is the market.. since Tuesday, shares have neen sliding, then today " off the cliff " it went. Words won't stop the MC damage and our share price collapse.
Yes, Peter and team have a lot of repair work to on Monday. You can hope, but I think the damage will suppress the share price until some time in Q4. Mean time, we might see more dilution in price due to pending shelf registration.
It is difficult to see Peter H. not impressively controlling events, PR's, web site, Mayo, and overall planning. He has more talent than has been demonstrated.
A bad day. I need some Tums or Prilosec unless today bad news follows those also.
Inov... you took time to offer a most excellent reply, thank you. This board is fortunate to have a number of skilled contributors. Q/4, 2019 is another anticipated milestone and set of presentations by MRKR. Thanks again.
While we await details on positive PC trials, I, having been here invested in TPIV and MRKR, would greatly appreciate a clear detailed update on TPIV110, 200, and Polystart. Those phase ll trials are years old. Anyone? Peter/ PL?
Correct.
Research indicates pancreatic cancer is the 11th most common cancer and there were 460,000 new cases reported in 2018.
We can hope that Marker can be granted the go ahead and treat some large percent at a good for business pricing.
Like all, I hope the data is compelling.
I still think a suitor in some form is or will be knocking on the door.
We can wish various outcomes, but in the rnd, it is business from the successful science. Meaning, we are the smaller retail investors.. Pharma knows how to take out the institutional investors at a share price they can say is optimal.
Any offer, at any future time will be out weighed by our interests. Management is akways taken care of. Any offer to purchase is subject to a shareholder vote. Need I say more?
There could be partnership, a product line purchase, or the whole entity.
However, today, no need to get " worked up
".
Marker is doing very well..
All eyes are on PC and AML clinical trials. I would like to read about the results of TP 100. 110, 200, and Polystart where millions have been invested.
As to being acquired, many of you reject the very idea. So be it, but add in that big pharma has contact channels and narketing and vast staffs that we cant even imagine. Additionally, if ( a big if) you were offered between $100 and $200 per share, my bet is you would take it.
Going it alone, results in little EPS and even with a P/E of 20, the MC would be $3-4 billion.. of course more with more issued shares. Not stirring the pot here, just considering a wider view. I do hold my thinking that an offer will come to Peter.
06/13/'19.. Market Watch article on big Pharmas intent on Cancer bios M & A.
My thought is that Marker is on several corporate radars. This year.
At the annual meeting. I trust that there will be an update. If asked by analysts or share holders, as to the two clinical trials which have received both orphan drug and fast track status...this is 2+ years old... time to relate what is going on.
Also, I hope some asks, when will you updaye the web site to give better info and more of the Marker theraputics investigations and results.
Lastly, when did this site become the I-hub morgue?
Peter Hoang, toss the market an IR " bone" and reverse this s/p bleeding. Before we know it, MRKR will be seeking funding and further dilution at $5.00 is much worse than dilution at $15.00.
MRKR,Annual shareholder meeting in Houston.. anyone going? Usually includes " meet and greet" and open questions.